Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Sells $44,892.17 in Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 3,499 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $12.83, for a total transaction of $44,892.17. Following the sale, the chief financial officer now owns 68,333 shares in the company, valued at $876,712.39. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Houte Hans Van also recently made the following trade(s):

• On Tuesday, April 30th, Houte Hans Van sold 1,387 shares of Nurix Therapeutics stock. The stock was sold at an average price of $12.04, for a total transaction of $16,699.48.
• On Friday, February 16th, Houte Hans Van sold 6,812 shares of Nurix Therapeutics stock. The shares were sold at an average price of $10.02, for a total transaction of $68,256.24.

Nurix Therapeutics Price Performance

NRIX stock traded down $0.35 during mid-day trading on Thursday, reaching $12.73. The company had a trading volume of 1,200,167 shares, compared to its average volume of 949,614. The company has a market capitalization of $625.68 million, a price-to-earnings ratio of -4.88 and a beta of 2.10. Nurix Therapeutics, Inc. has a 52 week low of $4.22 and a 52 week high of $18.12. The stock has a 50 day simple moving average of $13.76 and a two-hundred day simple moving average of $9.86.

Nurix Therapeutics (NASDAQ:NRIX) last released its earnings results on Thursday, February 15th. The company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.26). The firm had revenue of $15.16 million during the quarter, compared to the consensus estimate of $30.66 million. Nurix Therapeutics had a negative net margin of 178.93% and a negative return on equity of 67.08%. On average, equities analysts predict that Nurix Therapeutics, Inc. will post -3.15 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Royal Bank of Canada boosted their price target on Nurix Therapeutics from $22.00 to $23.00 and gave the company an “outperform” rating in a report on Thursday, April 11th. Robert W. Baird boosted their target price on Nurix Therapeutics from $24.00 to $25.00 and gave the company an “outperform” rating in a research note on Thursday, April 11th. Needham & Company LLC reaffirmed a “buy” rating and set a $31.00 price target on shares of Nurix Therapeutics in a research report on Tuesday, April 9th. Wells Fargo & Company lowered their price objective on shares of Nurix Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a report on Friday, February 16th. Finally, HC Wainwright reduced their target price on shares of Nurix Therapeutics from $35.00 to $19.00 and set a “buy” rating for the company in a report on Tuesday, February 20th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $21.33.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of NRIX. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Nurix Therapeutics by 27.3% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 30,904 shares of the company’s stock valued at $454,000 after purchasing an additional 6,628 shares during the period. J.W. Cole Advisors Inc. acquired a new position in Nurix Therapeutics during the first quarter worth approximately $265,000. China Universal Asset Management Co. Ltd. raised its stake in Nurix Therapeutics by 67.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 9,404 shares of the company’s stock valued at $138,000 after buying an additional 3,793 shares during the period. Wellington Management Group LLP lifted its position in shares of Nurix Therapeutics by 41.6% in the fourth quarter. Wellington Management Group LLP now owns 205,324 shares of the company’s stock valued at $2,119,000 after buying an additional 60,271 shares during the last quarter. Finally, Pennant Investors LP acquired a new stake in shares of Nurix Therapeutics in the fourth quarter valued at approximately $586,000.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.